Argus Like Gilead's Filgotnib Drug, Call It A 'blockbuster product', Says Galapagos 'warrants attention'

Argus says Galapagos ADR GLPG though not covered by the firm, warrants attention following Gilead GILD news of a collaboration deal announced on Friday.

Argus sees Gilead cashflow helping to expand the drug pipeline.

The advantage of fibfotnib over alternatives is that it is a pill, no injection required. If approved, Argus believes the drug could hit the market in 2019 as a viable alternative to Humira's offering and other anti-TNF drugs.